Pyromania

Summary

Pyromania (MONDO:0001522) is a disease and 1 clinical trial. Top therapeutic interventions include naltrexone. A subtype of impulse control disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pyromania
Mondo ID	MONDO:0001522
MeSH	D005391
DOID	DOID:12402
ICD-10-CM	F63.1
ICD-11	1532500290
NCIT	C94334
SNOMED CT	600009
UMLS	C0016142
MedGen	42028
Is cancer (heuristic)	no

Also known as: firesetting behaviour

Disease family

This is a subtype of impulse control disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › impulse control disorder › pyromania

Related subtypes (6): kleptomania, intermittent explosive disorder, Kluver-Bucy syndrome, pathological gambling, trichotillomania, primary polydipsia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00467454	PHASE2	WITHDRAWN	Naltrexone in the Treatment of Pyromania

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NALTREXONE	4	1